Moberg Pharma´s Interim report January - March 2022
EUROPEAN MARKETING AUTHORIZATION APPLICATION SUBMITTED AND NORTH AMERICAN PHASE 3 STUDY STARTEDFIRST QUARTER JAN-MAR 2022 · EBITDA SEK -4.8 million (-5.4) * · Operating profit (EBIT) SEK -5.4 million (-6.1) * · Profit after tax SEK -4.4 million (-5.0) * · Total profit SEK -4,4 million (18.6) · Diluted earnings per share SEK -0.10 (0.46) * · Cash and cash equivalents amounted to SEK 73.4 million (133.6) * All comparative figures refer to continuing operations SIGNIFICANT EVENTS IN THE FIRST QUARTER · Moberg Pharma submitted a marketing authorization application